Compare MRVI & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRVI | NUS |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.8M | 343.1M |
| IPO Year | 2020 | 1996 |
| Metric | MRVI | NUS |
|---|---|---|
| Price | $3.41 | $7.65 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.13 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 392.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | 14.29 | ★ 207.80 |
| EPS | N/A | ★ 3.18 |
| Revenue | $185,743,000.00 | ★ $3,176,718,000.00 |
| Revenue This Year | $12.44 | N/A |
| Revenue Next Year | $7.90 | $7.14 |
| P/E Ratio | ★ N/A | $2.45 |
| Revenue Growth | N/A | ★ 48.98 |
| 52 Week Low | $1.70 | $5.32 |
| 52 Week High | $4.11 | $14.62 |
| Indicator | MRVI | NUS |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 51.05 |
| Support Level | $3.25 | $7.03 |
| Resistance Level | $3.99 | $10.90 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 81.08 | 71.86 |
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.